Skip to main content

Table 2 Disease burden at baseline (all treatment groups combined)

From: Ixekizumab and complete resolution of enthesitis and dactylitis: integrated analysis of two phase 3 randomized trials in psoriatic arthritis

Characteristic, mean (SD) LEI > 0
(N = 403)a
LDI-B > 0
(N = 155)a
Integrated analysis set
(N = 679)
Pt assessment of joint pain, mm n = 392
63.7 (19.7)
n = 151
66.9 (20.7)
n = 665
61.4 (21.1)
PtGA of disease activity, mm n = 392
64.6 (20.9)
n = 151
68.6 (21.1)
n = 665
63.9 (20.8)
HAQ-DI total score n = 391
1.3 (0.6)
n = 151
1.3 (0.7)
n = 664
1.2 (0.6)
EQ-5D 5L n = 389
0.6 (0.2)
n = 151
0.5 (0.2)
n = 661
0.6 (0.2)
 EQ-5D VAS n = 389
52.5 (19.8)
n = 151
52.6 (21.9)
n = 661
54.1 (20.9)
  1. Abbreviations: EQ-5D 5L EuroQoL-5 Dimensions 5 level, HAQ-DI Health Assessment Questionnaire-Disability Index, N number of patients in analysis population, n number of patients with non-missing data, Pt patient, PtGA patient global assessment, VAS visual analogue scale
  2. aBaseline enthesitis defined as a baseline LEI score > 0 and baseline dactylitis defined as a baseline LDI-B score > 0